# GSK agrees to acquire Nuvalent for $10.6 billion in landmark oncology deal

> ma · REPORTED · 2026-06-09

GSK entered a definitive agreement on June 9, 2026 to acquire Boston-based precision oncology biotech Nuvalent for $10.6 billion ($124/share, a 40% premium), gaining two late-stage best-in-class NSCLC kinase inhibitors — zidesamtinib (ROS1) and neladalkib (ALK) — both currently under FDA review for 2026 approval decisions. The deal is one of the largest biopharma M&A transactions of 2026 and marks a strategic pivot for GSK into lung cancer.

- Company: GSK / Nuvalent
- Sector: oncology
- Primary source: https://www.cnbc.com/2026/06/09/gsk-in-talks-to-acquire-nuvalent-for-more-than-9-billion.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.